Prostate Cancer in Jordanian-Arab Population: ERG Status and Relationship with Clinicopathologic Characteristics

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 2017 May 28

PMID 28550496

Citations 5

Authors

Najla Aldaoud

Nour Abdo

Samir Al Bashir

Mohammad Alqudah

Noor Marji

Hiba Alzoubi

Rami Alazab

Kiril Trpkov

Affiliations

Soon will be listed here.

Abstract

TMPRSS2/ERG fusion was found to be the most common genetic event in prostate adenocarcinoma. There is a strong correlation between the fusion and ERG-positive immunostaining. Many studies showed racial variation in ERG expression in prostate cancer patients. There is no data however on the rate of ERG-positive cancer in Jordanian or Arab population. We evaluated the frequency and the significance of ERG fusion in Jordanian-Arab population using immunohistochemistry for ERG. The cohort included 193 prostate cancer specimens: 109 needle core biopsies, 45 radical prostatectomies, 37 transurethral resections of prostate, and 2 enucleation specimens. We found ERG reactivity in 64 (33.2%) of evaluated cases. The observed ERG frequency in the Jordanian-Arab population is lower than the one documented in North America, but it is higher than in Asian patient cohorts. The ERG positivity was significantly associated with lower baseline prostate-specific antigen but was unrelated to patient age, Gleason Score, or the novel Gleason Grade Groups. In the 45 prostatectomy cases, ERG did not correlate with the pathologic stage, margin, nodal status, and the biochemical recurrence, and it did not appear to represent an important prognosticator.

Citing Articles

PTEN, ERG, SPINK1, and TFF3 Status and Relationship in a Prostate Cancer Cohort from Jordanian Arab Population.

Al Bashir S, Alorjani M, Kheirallah K, Al Hamad M, Haddad H, Al-Dwairy A Medicina (Kaunas). 2024; 60(1).

PMID: 38256434 PMC: 10821453. DOI: 10.3390/medicina60010174.

Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.

Bakker A, Slack J, Palanisamy N, Carskadon S, Ghosh S, Khalifeh I J Cancer Res Clin Oncol. 2022; 149(7):3721-3728.

PMID: 35982181 DOI: 10.1007/s00432-022-04279-5.

Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.

Abdelsalam R, Khalifeh I, Box A, Kalantarian M, Ghosh S, Abou-Ouf H J Cancer Res Clin Oncol. 2020; 146(7):1701-1709.

PMID: 32350606 DOI: 10.1007/s00432-020-03221-x.

ERG expression in prostate cancer biopsies with and without high-grade prostatic intraepithelial neoplasia: a study in Jordanian Arab patients.

Aldaoud N, Graboski-Bauer A, Abdo N, Al Bashir S, Oweis A, Ebwaini H Res Rep Urol. 2019; 11:149-155.

PMID: 31192172 PMC: 6535407. DOI: 10.2147/RRU.S207843.

The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature.

Carneiro A, Barbosa A, Takemura L, Kayano P, Moran N, Chen C Front Oncol. 2018; 8:377.

PMID: 30280090 PMC: 6153326. DOI: 10.3389/fonc.2018.00377.

References

Epstein J, Egevad L, Amin M, Delahunt B, Srigley J, Humphrey P . The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2015; 40(2):244-52. DOI: 10.1097/PAS.0000000000000530. View

Dong J, Xiao L, Sheng L, Xu J, Sun Z . TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China. Asian Pac J Cancer Prev. 2014; 15(7):3099-103. DOI: 10.7314/apjcp.2014.15.7.3099. View

Shah R, Tadros Y, Brummell B, Zhou M . The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers. Hum Pathol. 2012; 44(5):786-94. DOI: 10.1016/j.humpath.2012.06.024. View

Park K, Dalton J, Narayanan R, Barbieri C, Hancock M, Bostwick D . TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol. 2013; 32(3):206-11. PMC: 3887478. DOI: 10.1200/JCO.2013.49.8386. View

Hilal L, Shahait M, Mukherji D, Charafeddine M, Farhat Z, Temraz S . Prostate Cancer in the Arab World: A View From the Inside. Clin Genitourin Cancer. 2015; 13(6):505-11. DOI: 10.1016/j.clgc.2015.05.010. View

Szasz A, Majoros A, Rosen P, Srivastava S, Dobi A, Szendroi A . Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma. Int Urol Nephrol. 2013; 45(3):727-33. PMC: 3691333. DOI: 10.1007/s11255-013-0406-2. View

Verdu M, Trias I, Roman R, Rodon N, Garcia-Pelaez B, Calvo M . ERG expression and prostatic adenocarcinoma. Virchows Arch. 2013; 462(6):639-44. DOI: 10.1007/s00428-013-1415-3. View

Han B, Suleman K, Wang L, Siddiqui J, Sercia L, Magi-Galluzzi C . ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol. 2010; 34(4):478-85. DOI: 10.1097/PAS.0b013e3181d6827b. View

Minner S, Enodien M, Sirma H, Luebke A, Krohn A, Mayer P . ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res. 2011; 17(18):5878-88. DOI: 10.1158/1078-0432.CCR-11-1251. View

10.

Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R . TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate. 2010; 71(5):489-97. DOI: 10.1002/pros.21265. View

11.

Furusato B, Tan S, Young D, Dobi A, Sun C, Mohamed A . ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010; 13(3):228-37. PMC: 3010744. DOI: 10.1038/pcan.2010.23. View

12.

Alghamidi I, Hussain I, Alghamdi M, El-Sheemy M . The incidence rate of prostate cancer in Saudi Arabia: an observational descriptive epidemiological analysis of data from the Saudi Cancer Registry 2001-2008. Hematol Oncol Stem Cell Ther. 2013; 7(1):18-26. DOI: 10.1016/j.hemonc.2013.10.001. View

13.

WATANABE , Nakayama , Shiraishi , Stemmermann , Yatani . Comparative studies of prostate cancer in Japan versus the United States. A review. Urol Oncol. 2000; 5(6):274-283. DOI: 10.1016/s1078-1439(00)00092-2. View

14.

Gao X, Li L, Zhou F, Xie K, Shao C, Su Z . ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis. Clin Cancer Res. 2012; 18(15):4163-72. DOI: 10.1158/1078-0432.CCR-11-2449. View

15.

Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P . Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2007; 27(3):253-63. PMC: 2646890. DOI: 10.1038/sj.onc.1210640. View

16.

van Leenders G, Boormans J, Vissers C, Hoogland A, Bressers A, Furusato B . Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol. 2011; 24(8):1128-38. DOI: 10.1038/modpathol.2011.65. View

17.

Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T . ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod Pathol. 2010; 23(11):1492-8. DOI: 10.1038/modpathol.2010.149. View

18.

Schaefer G, Mosquera J, Ramoner R, Park K, Romanel A, Steiner E . Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer. Prostate Cancer Prostatic Dis. 2013; 16(2):132-8. PMC: 3655380. DOI: 10.1038/pcan.2013.4. View

19.

Saramaki O, Harjula A, Martikainen P, Vessella R, Tammela T, Visakorpi T . TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res. 2008; 14(11):3395-400. DOI: 10.1158/1078-0432.CCR-07-2051. View

20.

Epstein J, Allsbrook Jr W, Amin M, Egevad L . The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29(9):1228-42. DOI: 10.1097/01.pas.0000173646.99337.b1. View